US8173644B2ActiveUtilityPatentIndex 60
3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
Est. expiryJan 3, 2027(~0.5 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/00A61P 25/16A61P 25/18A61P 25/28C07D 498/04
60
PatentIndex Score
2
Cited by
110
References
7
Claims
Abstract
This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, an in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to a compound useful for treatment of such conditions, and methods of using this compound for such treatment.
Claims
exact text as granted — not AI-modified1. A compound of the formula:
or a pharmaceutically acceptable addition salt of an acid or base thereof.
2. A method for treating a condition selected from schizophrenia, Parkinson's disease, and Alzheimer's disease in a subject in need thereof, said method comprising administering to said subject, in a pharmaceutically acceptable carrier, an effective amount of a compound according to claim 1 .
3. The method according to claim 2 wherein said condition is schizophrenia.
4. The method according to claim 2 wherein said condition is Parkinson's disease.
5. The method according to claim 2 wherein said condition is Alzheimer's disease.
6. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier, additive or excipient.
7. The composition according to claim 6 wherein said compound comprises about 0.5% to about 75% by weight of said composition and said carrier, additive or excipient comprises about 25% to about 95.5% of said composition.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.